ArticleBMC cancer2019

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.

Audrey Petitjean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.